Shattuck Labs, Inc.: directors' dealings · United States · SEC (Form 4)

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (ticker: STTK) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. Founded in 2016, the company is organized around research and development operations in Durham, North Carolina, and a corporate office in Austin, Texas. Its business is centered on the discovery and development of potential therapies for inflammatory and immune-mediated diseases, positioning Shattuck as a clinical-stage biotech rather than a commercial-stage pharmaceutical company. For investors, the key question is not current product revenue, but rather the probability that one or more of its pipeline assets can generate clinically meaningful data and ultimately create licensing or commercial value. Scientifically, Shattuck Labs has built its strategy around the biology of TNF superfamily receptors, especially the DR3/TL1A signaling axis. The company describes itself as developing next-generation monoclonal and bispecific antibodies designed to modulate these pathways. Its lead program is SL-325, a first-in-class DR3 blocking antibody being advanced in inflammatory disease indications. This focus is important because the company has recently sharpened its pipeline strategy, emphasizing immunology and inflammation after prioritizing programs and discontinuing others. That narrower focus can improve capital efficiency, but it also increases dependence on a small number of clinical assets. From a competitive standpoint, Shattuck Labs remains a small-cap biotech with meaningful execution risk. It is not a diversified large pharma group and does not have a broad commercial portfolio to cushion setbacks. Its market position is therefore defined by scientific differentiation, clinical milestones, and the ability to extend cash runway. In the highly competitive immunology landscape, the company’s challenge is to generate data strong enough to stand out against larger peers developing therapies for similar inflammatory and autoimmune indications. At the same time, its DR3-focused approach gives it a more focused narrative than many platform biotechs. Recent developments have been material. In its March 2026 year-end update, Shattuck said SL-325 Phase 1 enrollment was nearing completion, with human data expected in the second quarter of 2026 and a Phase 2 trial in Crohn’s disease expected to start in the third quarter of 2026. The company also disclosed a strengthened balance sheet after recent capital raises and said its current cash resources, together with proceeds from an at-the-market facility and assuming warrant exercise, were expected to fund operations into 2029 under its plans. For international equity investors, STTK is a classic development-stage biotech story: high risk, binary clinical catalysts, and potential upside tied to proof-of-concept execution on NASDAQ in the United States.